Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective study
Abstract Background A significant decrease in antibody titres several months after COVID-19 primary vaccination in end-stage kidney disease (ESKD) patients receiving maintenance haemodialysis has recently been reported. The waning in antibody titres has led to the recommendations for a booster dose...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-05-01
|
| Series: | BMC Nephrology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12882-023-03218-x |
| _version_ | 1797811596330795008 |
|---|---|
| author | Metalia Puspitasari Prenali D. Sattwika Auliana R. P. Hidayat Wynne Wijaya Yulia Wardhani Umi S. Intansari Nyoman Kertia Bambang Purwanto Jarir At Thobari |
| author_facet | Metalia Puspitasari Prenali D. Sattwika Auliana R. P. Hidayat Wynne Wijaya Yulia Wardhani Umi S. Intansari Nyoman Kertia Bambang Purwanto Jarir At Thobari |
| author_sort | Metalia Puspitasari |
| collection | DOAJ |
| description | Abstract Background A significant decrease in antibody titres several months after COVID-19 primary vaccination in end-stage kidney disease (ESKD) patients receiving maintenance haemodialysis has recently been reported. The waning in antibody titres has led to the recommendations for a booster dose to increase the antibody titres after vaccination. Consequently, it is crucial to analyse the long-term humoral immune responses after COVID-19 primary vaccination and assess the immunogenicity and safety of booster doses in haemodialysis (HD) patients. Methods Patients on maintenance haemodialysis who received the primary vaccine of CoronaVac (Sinovac) vaccine were administered with BNT162b2 (Pfizer-BioNTech) as the booster dose. The immunogenicity was assessed before (V1), one month (V2) and eight months (V3) after the primary vaccination, as well as one month after the booster dose (V4). Patients were followed up one month after the booster dose to assess the adverse events (AEs). Results The geometric mean titre (GMT) of anti-SARS-CoV-2 S-RBD IgG antibody at 8 months after the primary vaccination increased significantly to 5,296.63 (95%CI: 2,930.89–9,571.94) U/mL (p = < 0.0001) compared to before the primary vaccination. The GMT also increased significantly to 19,142.56 (95% CI: 13,489.63–27,227.01) U/mL (p < 0.0001) 1 month after the booster vaccine. Meanwhile, the median inhibition rate of neutralizing antibodies (NAbs) at 8 months after the primary vaccine and 1 month after the booster dose were not significantly different (p > 0.9999). The most common AEs after the booster dose included mild pain at the injection site (55.26%), mild fatigue (10.53%), and swelling at the injection site (10.53%). No serious AEs were reported. Conclusions The majority of ESKD patients on haemodialysis mounted a good antibody response to the BNT162b2 booster vaccination with tolerable adverse events. |
| first_indexed | 2024-03-13T07:25:04Z |
| format | Article |
| id | doaj.art-264f28df7dce470ab090c118227aa27f |
| institution | Directory Open Access Journal |
| issn | 1471-2369 |
| language | English |
| last_indexed | 2024-03-13T07:25:04Z |
| publishDate | 2023-05-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Nephrology |
| spelling | doaj.art-264f28df7dce470ab090c118227aa27f2023-06-04T11:23:24ZengBMCBMC Nephrology1471-23692023-05-0124111410.1186/s12882-023-03218-xImmunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective studyMetalia Puspitasari0Prenali D. Sattwika1Auliana R. P. Hidayat2Wynne Wijaya3Yulia Wardhani4Umi S. Intansari5Nyoman Kertia6Bambang Purwanto7Jarir At Thobari8Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General HospitalDepartment of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General HospitalDepartment of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General HospitalDepartment of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General HospitalDepartment of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General HospitalDepartment of Clinical Pathology and Laboratory Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General HospitalDepartment of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General HospitalDepartment of Internal Medicine, Faculty of Medicine, Universitas Sebelas MaretClinical Epidemiology and Biostatistics Unit, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General HospitalAbstract Background A significant decrease in antibody titres several months after COVID-19 primary vaccination in end-stage kidney disease (ESKD) patients receiving maintenance haemodialysis has recently been reported. The waning in antibody titres has led to the recommendations for a booster dose to increase the antibody titres after vaccination. Consequently, it is crucial to analyse the long-term humoral immune responses after COVID-19 primary vaccination and assess the immunogenicity and safety of booster doses in haemodialysis (HD) patients. Methods Patients on maintenance haemodialysis who received the primary vaccine of CoronaVac (Sinovac) vaccine were administered with BNT162b2 (Pfizer-BioNTech) as the booster dose. The immunogenicity was assessed before (V1), one month (V2) and eight months (V3) after the primary vaccination, as well as one month after the booster dose (V4). Patients were followed up one month after the booster dose to assess the adverse events (AEs). Results The geometric mean titre (GMT) of anti-SARS-CoV-2 S-RBD IgG antibody at 8 months after the primary vaccination increased significantly to 5,296.63 (95%CI: 2,930.89–9,571.94) U/mL (p = < 0.0001) compared to before the primary vaccination. The GMT also increased significantly to 19,142.56 (95% CI: 13,489.63–27,227.01) U/mL (p < 0.0001) 1 month after the booster vaccine. Meanwhile, the median inhibition rate of neutralizing antibodies (NAbs) at 8 months after the primary vaccine and 1 month after the booster dose were not significantly different (p > 0.9999). The most common AEs after the booster dose included mild pain at the injection site (55.26%), mild fatigue (10.53%), and swelling at the injection site (10.53%). No serious AEs were reported. Conclusions The majority of ESKD patients on haemodialysis mounted a good antibody response to the BNT162b2 booster vaccination with tolerable adverse events.https://doi.org/10.1186/s12882-023-03218-xCOVID-19 vaccinesBoosterEnd-stage renal diseaseHaemodialysisImmunogenicitySafety |
| spellingShingle | Metalia Puspitasari Prenali D. Sattwika Auliana R. P. Hidayat Wynne Wijaya Yulia Wardhani Umi S. Intansari Nyoman Kertia Bambang Purwanto Jarir At Thobari Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective study BMC Nephrology COVID-19 vaccines Booster End-stage renal disease Haemodialysis Immunogenicity Safety |
| title | Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective study |
| title_full | Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective study |
| title_fullStr | Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective study |
| title_full_unstemmed | Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective study |
| title_short | Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective study |
| title_sort | immunogenicity and safety of covid 19 bnt162b2 booster vaccine in end stage kidney disease patients receiving haemodialysis in yogyakarta indonesia a cohort prospective study |
| topic | COVID-19 vaccines Booster End-stage renal disease Haemodialysis Immunogenicity Safety |
| url | https://doi.org/10.1186/s12882-023-03218-x |
| work_keys_str_mv | AT metaliapuspitasari immunogenicityandsafetyofcovid19bnt162b2boostervaccineinendstagekidneydiseasepatientsreceivinghaemodialysisinyogyakartaindonesiaacohortprospectivestudy AT prenalidsattwika immunogenicityandsafetyofcovid19bnt162b2boostervaccineinendstagekidneydiseasepatientsreceivinghaemodialysisinyogyakartaindonesiaacohortprospectivestudy AT aulianarphidayat immunogenicityandsafetyofcovid19bnt162b2boostervaccineinendstagekidneydiseasepatientsreceivinghaemodialysisinyogyakartaindonesiaacohortprospectivestudy AT wynnewijaya immunogenicityandsafetyofcovid19bnt162b2boostervaccineinendstagekidneydiseasepatientsreceivinghaemodialysisinyogyakartaindonesiaacohortprospectivestudy AT yuliawardhani immunogenicityandsafetyofcovid19bnt162b2boostervaccineinendstagekidneydiseasepatientsreceivinghaemodialysisinyogyakartaindonesiaacohortprospectivestudy AT umisintansari immunogenicityandsafetyofcovid19bnt162b2boostervaccineinendstagekidneydiseasepatientsreceivinghaemodialysisinyogyakartaindonesiaacohortprospectivestudy AT nyomankertia immunogenicityandsafetyofcovid19bnt162b2boostervaccineinendstagekidneydiseasepatientsreceivinghaemodialysisinyogyakartaindonesiaacohortprospectivestudy AT bambangpurwanto immunogenicityandsafetyofcovid19bnt162b2boostervaccineinendstagekidneydiseasepatientsreceivinghaemodialysisinyogyakartaindonesiaacohortprospectivestudy AT jariratthobari immunogenicityandsafetyofcovid19bnt162b2boostervaccineinendstagekidneydiseasepatientsreceivinghaemodialysisinyogyakartaindonesiaacohortprospectivestudy |